Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASRTNASDAQ:LFCRNASDAQ:OMERNASDAQ:PGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASRTAssertio$0.63-4.5%$0.65$0.51▼$1.80$60.26M0.29646,322 shs432,219 shsLFCRLifecore Biomedical$6.94+3.4%$6.69$3.68▼$7.99$256.96M0.65237,668 shs168,447 shsOMEROmeros$3.21-0.3%$4.80$2.97▼$13.60$188.08M2.21696,321 shs1.23 million shsPGENPrecigen$1.45-2.7%$1.43$0.65▼$2.17$428.01M1.851.37 million shs2.11 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASRTAssertio0.00%-0.43%-11.42%-12.61%-42.80%LFCRLifecore Biomedical0.00%+3.12%+4.05%+5.95%+41.92%OMEROmeros0.00%-5.59%-0.31%-64.73%-21.52%PGENPrecigen0.00%-4.61%+4.32%-19.89%-7.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASRTAssertio1.6572 of 5 stars3.51.00.00.00.60.81.3LFCRLifecore Biomedical2.1261 of 5 stars2.33.00.00.01.84.20.6OMEROmeros3.6507 of 5 stars3.40.00.04.42.51.70.6PGENPrecigen3.6646 of 5 stars3.51.00.04.71.11.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASRTAssertio 3.00Buy$2.75337.06% UpsideLFCRLifecore Biomedical 2.50Moderate Buy$8.0015.27% UpsideOMEROmeros 2.83Moderate Buy$18.00460.75% UpsidePGENPrecigen 3.00Buy$6.00313.79% UpsideCurrent Analyst Ratings BreakdownLatest ASRT, OMER, LFCR, and PGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025PGENPrecigenJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$6.006/10/2025OMEROmerosHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.005/21/2025LFCRLifecore BiomedicalWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform5/19/2025ASRTAssertioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.50 ➝ $3.505/16/2025OMEROmerosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/15/2025PGENPrecigenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/13/2025ASRTAssertioAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/13/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.005/7/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.004/11/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.004/1/2025OMEROmerosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASRTAssertio$124.96M0.48$0.05 per share12.82$1.27 per share0.50LFCRLifecore Biomedical$128.26M2.00N/AN/A$0.37 per share18.76OMEROmerosN/AN/AN/AN/A($3.15) per shareN/APGENPrecigen$3.92M109.19N/AN/A$0.13 per share11.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASRTAssertio-$21.58M-$0.32N/A20.97N/A-25.72%-24.87%-10.87%8/6/2025 (Estimated)LFCRLifecore Biomedical$12.01M-$1.45N/AN/AN/A-35.90%-551.09%-13.89%8/15/2025 (Estimated)OMEROmeros-$156.82M-$2.65N/AN/AN/AN/AN/A-59.68%8/6/2025 (Estimated)PGENPrecigen-$126.24M-$0.56N/AN/AN/A-3,728.87%-279.20%-79.74%8/13/2025 (Estimated)Latest ASRT, OMER, LFCR, and PGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025OMEROmeros-$0.60-$0.65-$0.05-$0.58$0.40 millionN/A5/14/2025Q1 2025PGENPrecigen-$0.08-$0.07+$0.01-$0.18$0.50 million$1.34 million5/12/2025Q1 2025ASRTAssertio-$0.06-$0.14-$0.08-$0.14$27.52 million$26.49 million4/3/2025Q3 2025LFCRLifecore Biomedical-$0.14-$0.19-$0.05-$0.47$33.23 million$35.15 million3/31/2025Q4 2024OMEROmeros-$0.71-$0.63+$0.08-$0.54$0.40 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASRTAssertioN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/AOMEROmerosN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASRTAssertio0.361.661.35LFCRLifecore Biomedical66.362.711.59OMEROmerosN/A1.161.16PGENPrecigenN/A3.533.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASRTAssertio48.96%LFCRLifecore Biomedical83.36%OMEROmeros48.79%PGENPrecigen33.51%Insider OwnershipCompanyInsider OwnershipASRTAssertio4.00%LFCRLifecore Biomedical32.20%OMEROmeros12.90%PGENPrecigen47.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASRTAssertio2095.78 million91.95 millionOptionableLFCRLifecore Biomedical69037.03 million25.10 millionOptionableOMEROmeros21058.59 million51.04 millionOptionablePGENPrecigen190295.18 million156.15 millionOptionableASRT, OMER, LFCR, and PGEN HeadlinesRecent News About These CompaniesJMP Securities Reaffirms Market Outperform Rating for Precigen (NASDAQ:PGEN)June 14, 2025 | americanbankingnews.comCantor Fitzgerald Weighs in on Precigen FY2026 EarningsJune 13, 2025 | americanbankingnews.comPrecigen (NASDAQ:PGEN) Earns Market Outperform Rating from JMP SecuritiesJune 12, 2025 | marketbeat.comPrecigen, Inc.'s (NASDAQ:PGEN) market cap touched US$455m last week, benefiting both private equity firms who own 33% as well as institutionsJune 12, 2025 | finance.yahoo.comCantor Fitzgerald Estimates Precigen FY2026 EarningsJune 11, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 792,731 Shares of Precigen, Inc. (NASDAQ:PGEN)May 27, 2025 | marketbeat.comPrecigen (NASDAQ:PGEN) Downgraded to "Sell" Rating by Wall Street ZenMay 26, 2025 | marketbeat.comJ.P. Morgan Sticks to Its Sell Rating for Precigen (PGEN)May 20, 2025 | theglobeandmail.comPrecigen, Inc.: Precigen Reports First Quarter 2025 Financial Results and Business UpdatesMay 18, 2025 | finanznachrichten.deCantor Fitzgerald maintains Overweight on Precigen stockMay 17, 2025 | uk.investing.comPrecigen Reports First Quarter 2025 Financial Results and Business UpdatesMay 14, 2025 | prnewswire.comPrecigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11thApril 16, 2025 | prnewswire.comIs Precigen (PGEN) The Hot Biotech Stock Under $5?March 27, 2025 | msn.comPrecigen options imply 20.1% move in share price post-earningsMarch 20, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Edwards Lifesciences (EW)March 20, 2025 | markets.businessinsider.com4PGEN : Expert Outlook: Precigen Through The Eyes Of 4 AnalystsMarch 20, 2025 | benzinga.comPrecigen, Inc.: Precigen Reports Full Year 2024 Financial Results and Business UpdatesMarch 20, 2025 | finanznachrichten.dePrecigen Reports Progress and Financial Results for 2024March 19, 2025 | tipranks.comPrecigen, Inc. (PGEN) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | seekingalpha.comPrecigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue EstimatesMarch 19, 2025 | zacks.comPrecigen Reports Full Year 2024 Financial Results and Business UpdatesMarch 19, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBroadcom Slides on Solid Earnings, AI Outlook Still StrongBy Leo Miller | June 6, 2025View Broadcom Slides on Solid Earnings, AI Outlook Still StrongGE Aerospace Turns Engines Into Long-Term ProfitsBy Jeffrey Neal Johnson | June 21, 2025View GE Aerospace Turns Engines Into Long-Term ProfitsRed Robin's Comeback: Q1 Earnings Spark Investor HopesBy Jeffrey Neal Johnson | June 5, 2025View Red Robin's Comeback: Q1 Earnings Spark Investor HopesASRT, OMER, LFCR, and PGEN Company DescriptionsAssertio NASDAQ:ASRT$0.63 -0.03 (-4.54%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.66 +0.03 (+5.37%) As of 06/20/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Lifecore Biomedical NASDAQ:LFCR$6.94 +0.23 (+3.43%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$6.94 0.00 (0.00%) As of 06/20/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Omeros NASDAQ:OMER$3.21 -0.01 (-0.31%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.22 +0.00 (+0.16%) As of 06/20/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.Precigen NASDAQ:PGEN$1.45 -0.04 (-2.68%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.45 0.00 (0.00%) As of 06/20/2025 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
